No controlled studies have evaluated the safety of combining research peptides with approved MS medications like ocrelizumab, natalizumab, or fingolimod
Sociodemographic characteristics Diagnosis (vitamin B12 deficiency or pernicious anaemia), age, sex, education level, employment status, country of residence (England, Wales, Scotland, Northern Ireland, Republic of Ireland), region of residence (nine English regions, according to the Office for National Statistics, Wales, Scotland, and Northern Ireland) were assessed using the questions in Supplementary Table S1
Furthermore, all experiments were carried out under a blind protocol, and the effects were assessed by examiners who were completely unaware of the protocol
PLoS One 2014;9:e108210
But will give it another month to see if I can get better results Great fast service